7Z6 Stock Overview
A biotechnology company, engages in the discovery and development of dermacosmetic products and drugs for the treatment of serious diseases associated with diabetes and cancer. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 2 more risks
Coegin Pharma AB Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 0.32 |
| 52 Week High | SEK 0.74 |
| 52 Week Low | SEK 0.31 |
| Beta | 0.96 |
| 11 Month Change | -17.10% |
| 3 Month Change | -43.26% |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -47.54% |
Recent News & Updates
Recent updates
Shareholder Returns
| 7Z6 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -3.0% | -0.2% | 0.8% |
| 1Y | n/a | -16.9% | 9.1% |
Return vs Industry: Insufficient data to determine how 7Z6 performed against the German Biotechs industry.
Return vs Market: Insufficient data to determine how 7Z6 performed against the German Market.
Price Volatility
| 7Z6 volatility | |
|---|---|
| 7Z6 Average Weekly Movement | 10.0% |
| Biotechs Industry Average Movement | 6.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 7Z6's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: Insufficient data to determine 7Z6's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 1 | Jens Eriksson | coeginpharma.com |
Coegin Pharma AB, a biotechnology company, engages in the discovery and development of dermacosmetic products and drugs for the treatment of serious diseases associated with diabetes and cancer. Its products include AVX001 GEL drug candidate, which is in phase 2 clinical study for the treatment of actinic keratosis and in phase 1 clinical study for the treatment of basal cell carcinoma; AVX420 drug candidate in preclinical study for the indication of leukemia; FOL026, a peptide-based drug in preclinical study for the prevention of cardiovascular complications in diabetes; AVX420/FOL026 therapy in preclinical study for the treatment of kidney and liver fibrosis; and FOL005 for the treatment of stimulation of hair growth. The company was founded in 2005 and is based in Lund, Sweden.
Coegin Pharma AB Fundamentals Summary
| 7Z6 fundamental statistics | |
|---|---|
| Market cap | €7.04m |
| Earnings (TTM) | -€2.26m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-3.1x
P/E RatioIs 7Z6 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 7Z6 income statement (TTM) | |
|---|---|
| Revenue | SEK 0 |
| Cost of Revenue | SEK 16.00k |
| Gross Profit | -SEK 16.00k |
| Other Expenses | SEK 25.99m |
| Earnings | -SEK 26.00m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.28 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 7Z6 perform over the long term?
See historical performance and comparison